Nu-Med Plus (NUMD) Liabilities and Shareholders Equity (2011 - 2025)
Nu-Med Plus (NUMD) reported Liabilities and Shareholders Equity of $7911.0 for Q4 2025, down 15.6% on a YoY basis from $9373.0 in Q4 2024, and up 56.72% sequentially from $5048.0 in Q3 2025.
Nu-Med Plus (NUMD) Liabilities and Shareholders Equity (2011 - 2025) Analysis & Trends
Nu-Med Plus (NUMD) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $7911.0 in Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 15.6% year-over-year to $7911.0; the trailing twelve-month figure through Dec 2025 stood at $26295.0 (down 27.5% YoY), and the FY2025 full-year result was $7911.0, down 15.6% from the prior year.
- Liabilities and Shareholders Equity rose to $7911.0 in Q4 2025, from $5048.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $285013.0 in Q1 2021 to a low of $3168.0 in Q3 2022.
- A 5-year average of $36600.4 and a median of $10207.0 in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity tumbled 97.22% in 2022 and surged 645.26% in 2023, its largest moves.
- Tracing NUMD's Liabilities and Shareholders Equity over 5 years: stood at $22163.0 in 2021, then soared by 258.91% to $79545.0 in 2022, then plunged by 83.08% to $13456.0 in 2023, then plunged by 30.34% to $9373.0 in 2024, then retreated by 15.6% to $7911.0 in 2025.
- Business Quant data shows NUMD's Liabilities and Shareholders Equity at $7911.0 in Q4 2025, $5048.0 in Q3 2025, and $8163.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.39 Bn | 175.10 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 128.75 Bn | 125.87 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 108.59 Bn | 99.37 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 68.22 Bn | 66.77 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 47.59 Bn | 43.92 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 28.58 Bn | 27.46 Bn | 750.30 Mn | 6.63 Bn |
| 7 | GE HealthCare Technologies | 28.48 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 8 | Smith & Nephew | 26.96 Bn | 26.39 Bn | - | 10.46 Bn |
| 9 | Koninklijke Philips | 25.47 Bn | 22.34 Bn | 2.07 Bn | 31.92 Bn |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | 7,911.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7,911.00 |
| Sep 30, 2025 | 5,048.00 |
| Jun 30, 2025 | 8,163.00 |
| Mar 31, 2025 | 5,173.00 |
| Dec 31, 2024 | 9,373.00 |
| Sep 30, 2024 | 6,841.00 |
| Jun 30, 2024 | 11,041.00 |
| Mar 31, 2024 | 9,016.00 |
| Dec 31, 2023 | 13,456.00 |
| Sep 30, 2023 | 13,748.00 |
| Jun 30, 2023 | 36,547.00 |
| Mar 31, 2023 | 59,069.00 |
| Dec 31, 2022 | 79,545.00 |
| Sep 30, 2022 | 3,168.00 |
| Jun 30, 2022 | 8,440.00 |
| Mar 31, 2022 | 7,926.00 |
| Dec 31, 2021 | 22,163.00 |
| Sep 30, 2021 | 51,236.00 |
| Jun 30, 2021 | 89,130.00 |
| Mar 31, 2021 | 285,013.00 |